{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:28:12Z","timestamp":1777865292680,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T013966\/1"],"award-info":[{"award-number":["BB\/T013966\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["Z1ADA000424"],"award-info":[{"award-number":["Z1ADA000424"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118654","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:39:51Z","timestamp":1770741591000},"page":"118654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tailoring cariprazine for dual disorders via secondary pharmacophore optimization"],"prefix":"10.1016","volume":"307","author":[{"given":"Caleb D.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arina","family":"Ranjit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Robert","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-4072","authenticated-orcid":false,"given":"Amy Hauck","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118654_bib1","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2024","year":"2025"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118654_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YCO.0b013e328351a429","article-title":"Clinical presentations and diagnostic issues in dual diagnosis disorders","volume":"25","author":"Morojele","year":"2012","journal-title":"Curr. Opin. Psychiatr."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118654_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-007-0048-0","article-title":"Treatment of patients comorbid for addiction and other psychiatric disorders","volume":"9","author":"Brady","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1360-0443.2012.04010.x","article-title":"Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence","volume":"108","author":"Samet","year":"2013","journal-title":"Addict"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118654_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1176\/appi.ajp-rj.2024.190302","article-title":"A brief review of cariprazine","volume":"19","author":"Oldak","year":"2024","journal-title":"Am. J. Psychiatry Resid. J."},{"key":"10.1016\/j.ejmech.2026.118654_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2147\/NDT.S367922","article-title":"Switching clozapine to cariprazine in three patients with persistent symptoms of schizophrenia: a case series","volume":"18","author":"Duque-Yemail","year":"2022","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejmech.2026.118654_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/NDT.S298005","article-title":"Cariprazine in three acute patients with schizophrenia: a real-world experience","volume":"17","author":"Montes","year":"2021","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejmech.2026.118654_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.727666","article-title":"Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction","volume":"12","author":"Rodriguez Cruz","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejmech.2026.118654_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.878889","article-title":"Case report: functional and symptomatic improvement with cariprazine in various psychiatric patients: a case series","volume":"13","author":"Vannucchi","year":"2022","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118654_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1385925","article-title":"A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia","volume":"15","author":"Selvan","year":"2024","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118654_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1021\/acs.jmedchem.2c01624","article-title":"Dopamine D3\/D2 receptor ligands based on cariprazine for the treatment of psychostimulant use disorders that may be dual diagnosed with affective disorders","volume":"66","author":"Gogarnoiu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom11010104","article-title":"Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders","volume":"11","author":"Kiss","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.118654_bib14","series-title":"Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/7854_2022_347","article-title":"Current perspectives on selective dopamine D3 receptor antagonists\/partial agonists as pharmacotherapeutics for opioid and psychostimulant use disorders","author":"Newman","year":"2022"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118654_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-012-2906-7","article-title":"Cariprazine (RGH-188), a D3-Preferring dopamine D3\/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats","volume":"226","author":"Roman","year":"2013","journal-title":"Psychopharmacology"},{"issue":"13","key":"10.1016\/j.ejmech.2026.118654_bib16","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1111\/bph.70021","article-title":"ESG-1-60 and ESG-1-61: novel dopamine D3 receptor-preferring partial agonists\/antagonists that inhibit cocaine taking and seeking in rodents","volume":"182","author":"Soler-Cedeno","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118654_bib17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/acs.jmedchem.9b01105","article-title":"Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-Protein coupled receptors. The whole is greater than the sum of its parts","volume":"63","author":"Newman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118654_bib18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/mol.113.087833","article-title":"A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors","volume":"84","author":"Michino","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118654_bib19","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.5c00721","article-title":"Structure\u2013function activity relationships of cariprazine analogues with distinct G protein versus \u03b2-Arrestin activities at the dopamine D3 receptor","author":"Keegan","year":"2025","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118654_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/acs.jmedchem.6b01148","article-title":"Toward understanding the structural basis of partial agonism at the dopamine D3 receptor","volume":"60","author":"Michino","year":"2017","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118654_bib21","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1021\/acschembio.9b00342","article-title":"Molecular determinants of the intrinsic efficacy of the antipsychotic aripiprazole","volume":"14","author":"Klein Herenbrink","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118654_bib22","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1021\/jm401318w","article-title":"A structure-activity analysis of biased agonism at the dopamine D2 receptor","volume":"56","author":"Shonberg","year":"2013","journal-title":"J. Med. Chem."},{"issue":"91","key":"10.1016\/j.ejmech.2026.118654_bib23","doi-asserted-by":"crossref","first-page":"14167","DOI":"10.1039\/D0CC05532H","article-title":"Controlling receptor function from the extracellular vestibule of G-Protein coupled receptors","volume":"56","author":"Egyed","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118654_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.847788","article-title":"The impact of the secondary binding pocket on the pharmacology of class a GPCRS","volume":"13","author":"Egyed","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118654_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp.2005.079228","article-title":"Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder","volume":"77","author":"Potvin","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118654_bib26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41386-018-0285-4","article-title":"Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET Study in Humans","volume":"44","author":"Di Ciano","year":"2019","journal-title":"Nehropsychopharmacology"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118654_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10550490590949488","article-title":"Treatment compliance in patients with comorbid psychiatric and substance use disorders","volume":"14","author":"Herbeck","year":"2005","journal-title":"Am. J. Addict."},{"issue":"null","key":"10.1016\/j.ejmech.2026.118654_bib28","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2147\/PPA.S108678","article-title":"Professionals' perception on the management of patients with dual disorders","volume":"10","author":"Roncero","year":"2016","journal-title":"Patient Prefer. Adherence"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118654_bib29","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1016\/j.bmcl.2012.03.104","article-title":"Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3\/D2 receptors","volume":"22","author":"Agai-Csongor","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118654_bib30","article-title":"The impact of secondary site interactions on the binding specificity of bitopic dopamine D2\/D3 receptor ligands","volume":"15","author":"Egyed","year":"2025","journal-title":"Eur. J. Med. Chem. Rep"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118654_bib31","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1021\/acs.jmedchem.1c00611","article-title":"Novel dual-target Mu-Opioid receptor and dopamine D3 receptor ligands as potential nonaddictive pharmacotherapeutics for pain management","volume":"64","author":"Bonifazi","year":"2021","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118654_bib34","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118654_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118654_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118654_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib36","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118654_bib37","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ejmech.2026.118654_bib38","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.1021\/acs.jmedchem.3c01178","article-title":"2B determined: the future of the serotonin receptor 2B in drug discovery","volume":"66","author":"Bender","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118654_bib39","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine","volume":"13","author":"Kiss","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118654_bib40","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1124\/dmd.112.046482","article-title":"Pharmacokinetics of oral D-Serine in D-Amino acid oxidase knockout mice","volume":"40","author":"Rais","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib41","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1038\/s41467-024-51993-4","article-title":"A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site","volume":"15","author":"Arroyo-Urea","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118654_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115674","article-title":"Neutral sphingomyelinase 2 inhibitors based on the Pyrazolo[1,5-a]pyrimidin-3-amine scaffold","volume":"259","author":"Novotna","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118654_bib43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/acs.jmedchem.3c02037","article-title":"Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl alicyclic amines that improve metabolic stability and retain an atypical DAT inhibitor profile","volume":"67","author":"Okorom","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118654_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejmech.2019.03.015","article-title":"Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-Imidazole-2-Yl)-2,6-dialkoxyphenol scaffold","volume":"170","author":"Stepanek","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:12:01Z","timestamp":1777529521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["S0223523426000991"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118654","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring cariprazine for dual disorders via secondary pharmacophore optimization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118654"}}